wire - news in brief

« BACK

Health



Results 151 - 200 of 1655.


Environment - Health - 27.08.2018
How the cholera bacterium survives water predators
How the cholera bacterium survives water predators
EPFL scientists have deciphered mechanisms that help the cholera bacterium to survive grazing predators in aquatic environments. The cholera-causing bacterium, Vibrio cholerae , is commonly found in aquatic environments, such as oceans, ponds, and rivers. There, the bacterium has evolved formidable skills to ensure its survival, growth, and occasional transmission to humans, especially in endemic areas of the globe.

Health - Life Sciences - 27.08.2018
Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah (tisagenlecleucel)
The EC approval is based on the first global CAR-T registration trials, which included patients from eight European countries and demonstrated durable responses and a consistent safety profile in r/r

Careers / Employment - Health - 22.08.2018
Fostering Research Productivity in Côte d'Ivoire
Fostering Research Productivity in Côte d’Ivoire
Since 2000, the research productivity in Côte d'Ivoire has grown steadily above the regional and global rate, despite recurring economic pressures and socio-political unrest.

Health - Pharmacology - 20.08.2018
China National Drug Administration grants rapid approval of Roche’s Alecensa (alectinib) as a treatment for ALK-positive lung cancer
China National Drug Administration grants rapid approval of Roche's Alecensa (alectinib) as a treatment for ALK-positive lung cancer Approval follows priority review of Alecensa in China, just eight

Health - Life Sciences - 03.08.2018
PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease
European Medicines Agency PRIME (PRIority MEdicines) status is granted to medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options RG6042 has the potential to be the first therapy targeting the underlying cause of Huntington's disease, a fatal neurodegenerative rare disease Third PRIME designation for a Roche medicine Roche today announced that the European Medicines Agency (E

Health - Careers / Employment - 30.07.2018
Novartis marks a new era for migraine patients with the EU approval of Aimovig , a first-of-its-kind treatment specifically designed for migraine prevention
Novartis marks a new era for migraine patients with the EU approval of Aimovig , a first-of-its-kind treatment specifically designed for migraine prevention Patients on Aimovig (erenumab) in clinical

Health - 27.07.2018
Knowledge brokers connect research, policy and practice
Knowledge brokers connect research, policy and practice
Knowledge brokering is a technical term used to describe activities to facilitate mutual learning between researchers, practitioners and policy makers.

Health - Administration - 27.07.2018
Novartis combination Tafinlar + Mekinist receives positive CHMP opinion for adjuvant treatment of BRAF V600 mutation-positive melanoma
Phase III trial showed a 53% reduction in risk of recurrence or death with the combination of a BRAF and MEK inhibitor as adjuvant therapy versus placebo   Relapse-free survival benefit with Tafinlar

Health - 25.07.2018
Cross-Cultural Exchange on Health System Performance
Cross-Cultural Exchange on Health System Performance
A workshop was held on 16 to 20 July in Basel, Switzerland, bringing together over 60 Swiss TPH employees including 37 from 14 countries in West and Central Africa and the Middle East.

Health - Life Sciences - 23.07.2018
Novartis renews drug donation of Egaten (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke
Novartis extends agreement with the WHO for the donation of Egaten for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 millio

Health - Pharmacology - 19.07.2018
Roche’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with advanced lung cancer
Roche today announced that the Phase III IMpower132 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of Tecentriq (atezolizumab) plus chemoth

Health - Life Sciences - 18.07.2018
Novartis Kisqali now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
Novartis Kisqali now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women Kisqal

Business / Economics - Health - 18.07.2018
Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
Net sales grew 5% (cc , +7% USD) mainly driven by: Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU Entresto sales more than doubled to USD 239 millio

Pharmacology - Health - 18.07.2018
FDA grants Breakthrough Therapy Designation for Roche’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
FDA grants Breakthrough Therapy Designation for Roche's Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC) Roche today announced t

Health - 02.07.2018
Roche commences tender offer for all shares of Foundation Medicine, Inc. for US$ 137.00 per share in cash
Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Foundation Medicine, Inc.

Health - Pharmacology - 02.07.2018
Phase III IMpassion130 study showed Roche’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer
First Phase III immunotherapy study to demonstrate a statistically significant improvement in progression-free survival (PFS) in the intention-to-treat (ITT) and PD-L1 positive first-line metastatic

Health - Life Sciences - 29.06.2018
Novartis receives positive CHMP opinion for Kymriah for treating two aggressive blood cancers, marking important medical advance for patients in Europe
Novartis receives positive CHMP opinion for Kymriah for treating two aggressive blood cancers, marking important medical advance for patients in Europe First CHMP opinion for a CAR-T cell therapy in

Health - 28.06.2018
Novartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig (erenumab) in patients with chronic and episodic migraine
Novartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig (erenumab) in patients with chronic and episodic migraine Results from a one-year study of efficacy and

Health - Careers / Employment - 27.06.2018
Novartis International AG: Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month
Novartis International AG: Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month Study re

Health - Innovation / Technology - 27.06.2018

Health - 26.06.2018
Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin
Survey data published in JEADV show that patients experienced four different treatments and three medical professionals on average before finding an efficacious therapy New publication also highlight

Pharmacology - Health - 25.06.2018
Roche’s TECENTRIQ in combination with chemotherapy helped people with previously-untreated extensive-stage small cell lung cancer live significantly longer compared to chemotherapy
IMpower133 is the first Phase III study with an immunotherapy-based combination to show improvement in overall survival and progression-free survival in the initial treatment of extensive-stage small

Health - Life Sciences - 21.06.2018
Claudia Daubenberger Appointed Professor at the University of Basel
Claudia Daubenberger Appointed Professor at the University of Basel
The University of Basel appointed Claudia Daubenberger, Head of Clinical Immunology at Swiss TPH, as professor of Infection Biology and Immunology within the Faculty of Science.

Business / Economics - Health - 21.06.2018
Nurseries and crèches: what impact do they have on the development of children under three? - News
Nurseries and crèches: what impact do they have on the development of children under three? Insights from research at HEC Lausanne-UNIL An ever-increasing number of mothers with young children are returning to work.

Health - Pharmacology - 19.06.2018
Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology
Together, the companies will leverage expertise in genomics and molecular information to enhance the development of personalised medicines and care for patients with cancer Merger focuses on driving

Health - Innovation / Technology - 18.06.2018
Novartis International AG: Alcon AcrySof IQ PanOptix trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery
Novartis International AG: Alcon AcrySof IQ PanOptix trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery Better visual outcomes for patients with t

Health - Life Sciences - 16.06.2018
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
Overall response rate was 52% and median duration of response was not reached at a median follow-up of 14 months, signifying responses were durable   Patients had a 65% chance of being relapse-free o

Health - Life Sciences - 15.06.2018
Study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer
Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer Comparison of Jakavi (ruxolitinib) vs.

Health - Social Sciences - 15.06.2018
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients’ quality of life
Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%) About two-thirds of patients

Health - Life Sciences - 14.06.2018
Enigma of fatty acid metabolism solved: Enzyme shape controls its activity
Enigma of fatty acid metabolism solved: Enzyme shape controls its activity
Fats are essential for our body. The core components of all fats are fatty acids. Their production is initiated by the enzyme ACC.

Pharmacology - Health - 13.06.2018
FDA approves Roche’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery
FDA approves Roche's Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery Avastin is now approved for ten distinct uses across six different types of cancer in the United States Roche today announced that the US Food and Drug Administration (FDA) has approved Avastin (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin as a single agent, for the treatment of women with advanced (stage III or IV) ovarian cancer following initial surgical resection.

Pharmacology - Health - 11.06.2018
Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia
Approval based on phase III MURANO study showing Venclexta plus Rituxan reduced risk of disease progression or death by 81% compared to bendamustine plus Rituxan Roche , announced today that the Unit

Health - Social Sciences - 07.06.2018
Novartis announces JCO publication of Lutathera NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs
Novartis announces JCO publication of Lutathera NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs Patients repor

Pharmacology - Health - 05.06.2018
FDA grants Priority Review to Roche’s Hemlibra for people with haemophilia A without factor VIII inhibitors
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Hemlibra (emicizumab-kxwh) for adults and children with haemophilia A without factor VIII inhibitors.

Health - Innovation / Technology - 04.06.2018

Pharmacology - Health - 02.06.2018
Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer
Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell

Health - Chemistry - 02.06.2018
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna remain in remission almost three years after stopping therapy
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna remain in remission almost three years after stopping therapy ENESTop and ENESTfreedom data evaluate Treatmen

Health - Business / Economics - 01.06.2018
Sandoz receives positive CHMP opinion for proposed biosimilar adalimumab
Sandoz is seeking approval of proposed biosimilar adalimumab for use in all reference medicine indications including those in rheumatology, gastroenterology and dermatology Positive CHMP opinion base